Alerta

SUBLINGUAL COMPOSITIONS FOR FASUDIL

Resumen de: WO2025171484A1

Disclosed herein are sublingual formulations of fasudil and methods for using the same to treat neurological conditions such as ALS.

Compositions and Methods for Modulating Dopamine Receptor Activity

Resumen de: US2025262308A1

The present disclosure provides conjugates and systems for modulating the activity of a ligand-binding polypeptide such as a D2 dopamine receptor. Such conjugates comprising an affinity agent, a linker; a photoisomerizable group and a ligand that binds to a target ligand-binding polypeptide. The present disclosure provides methods of modulating the activity of a D2 dopamine receptor. The present disclosure provides methods of treating Parkinson's disease in an individual.

NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE

Resumen de: US2025263412A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).

ALPHA SYNUCLEIN THERAPEUTIC VACCINE

Resumen de: WO2025172592A1

The present invention relates to immunogenic compositions that can be employed for the prevention, alleviation or treatment of a condition associated with diseases, disorders and abnormalities associated with alpha synuclein (alpha synuclein, α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) ("pure" Lewy body dementia), Parkinson's disease dementia (PDD)), or Diffuse Lewy Body Disease.

COMPOSITIONS AND METHODS USING REELIN IN ALZHEIMER'S DISEASE

Resumen de: AU2023358527A1

Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.

COMPOSITIONS AND METHODS RELATED TO MODULATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-CD74 SIGNALING AND RELATED TREATMENTS FOR NEUROINFLAMMATORY CONDITIONS

Resumen de: WO2025171411A1

The present disclosure provides methods for preventing, treating, or delaying progression of neuroinflammatory CNS conditions, e.g., Alzheimer's disease, by administration of an agent that inhibits macrophage migration inhibitory factor (MIF)-CD74 signaling. In some embodiments the agent to be administered is a MIF-binding protein such as a MIF antibody. In other embodiments disclosed herein the agent is a targeting polynucleotide against MIF or CD74.

METHOD OF TREATING PARKINSON'S DISEASE WITH EXPANDED NATURAL KILLER CELLS

Resumen de: US2025255903A1

Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.

DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: WO2024184305A1

Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula -CH2n- with n = 0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.

THERAPEUTIC COMPOSITIONS WITH IMINO SUGARS FOR THE TREATMENT OF DISEASES WITH ACCUMULATION OF HEPARAN SULFATE

Resumen de: US2025255856A1

Compositions herein disclosed are conceived for the treatment and prevention of diseases caused by accumulation of heparan sulfate including mucopolysaccharidosis, Alzheimer's disease and cancers. These compositions include as active ingredient an iminosugar belonging to L-steric series and derivatives thereof. The L-iminosugars of this invention are able to reduce the levels of heparan sulfate in cells of patients affected by mucopolysaccharidosis and cancer, and to reduce the accumulation of amyloid plaques in a model of neurodegenerative disease. Therefore, the use of these compounds prevents the onset of symptoms associated with these diseases, thus improving the quality and length of life of patients suffering from diseases characterized by accumulation of heparan sulfate.

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

Resumen de: US2025257124A1

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

DRUG FOR TREATING NEURODEGENERATIVE DISEASE

Resumen de: WO2025168003A1

Provided are a pharmaceutical composition for preventing and/or treating neurodegenerative diseases and use thereof. The pharmaceutical composition comprises rivastigmine, liraglutide, and derivatives thereof; the pharmaceutical composition further comprises a sustained-release system, the sustained-release system can interact with the rivastigmine, the liraglutide, and the derivatives thereof to form a copolymer that enables sustained drug release, and the sustained-release system is a triblock hydrogel sustained-release system. The combination of the liraglutide and the rivastigmine can ameliorate the learning and memory impairments associated with Alzheimer's disease, with the effect superior to monotherapy and exhibiting a synergistic effect.

ALZHEIMER-TYPE DEMENTIA PREVENTING AGENT, AND METHOD FOR PRODUCING SAME

Resumen de: EP4599838A1

The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.

COMPOSITION AND METHODS FOR ENHANCING OR PROMOTING A HEALTHY METABOLIC AGING

Resumen de: EP4599696A2

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and/or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and/or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

ANTIAGING FOOD SUPPLEMENT FOR MEMORY DECREASE MANAGEMENT, MILD COGNITIVE IMPAIRMENT AND EARLY-STAGE ALZHEIMER'S AND PARKINSON'S DISEASE

Resumen de: GR20240100037A

The invented natural plant-based food supplement capsules are designed for the management of individuals suffering from memory impairment, mild cognitive impairment, or from early-stage Alzheimer's and Parkinson's disease. The natural plant-origin ingredients contained in the capsule are a combination of antioxidants offering better antioxidant, anti-apoptotic, and neuroprotective action; they penetrate the blood-brain barrier, acting on the neurons of the brain, and they inhibit the formation of amyloid-b proteins and Tau protein which are involved in neurodegenerative disorders, inhibitingthe progression and worsening of Alzheimer's and Parkinson's disease. Said capsules are designed for people wishing to take natural plant-origin products. Compared to the side effects of existing formulations, said capsules exhibit minimal side effects.

Variant RNAi

Resumen de: AU2025205501A1

18808542_1 (GHMatters) P43228AU01 Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington’s disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington’s disease. Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease. 18808542_1 (GHMatters) P43228AU01 ul u l r o v i d e d

EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION

Resumen de: AU2025205635A1

This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. ul h i s i n v e n t i o n p r o v i d e s w i t h a n e d a r a v o n e s u s p e n s i o n f o r o r a l a d m i n i s t r a t i o n h a v i n g e x c e l l e n t u l b i o a v a i l a b i l i t y t i s e x p e c t e d t h a t b u r d e n o n p a t i e n t s a n d c a r e w o r k e r s c a n b e r e d u c e d t h e r e b y

Anti-Amyloidogenic Curcumin Analogues

Resumen de: US2025250218A1

Extended chalcone compounds with anti-amylogenic activity were prepared and found to lack cytotoxicity and to promote neuroprotection. Testing on an animal model for Alzheimer's Disease revealed improvements in brain function using the high affinity compounds. The compounds inhibited the aggregation of Aβ42 but not its synthesis. The compounds can be used in new therapies for the prevention and treatment of Alzheimer's disease, including in conjunction with antibodies directed at removing amyloid plaques.

NOVEL FUSION PROTEIN FOR ELIMINATING NEURODEGENERATIVE DISEASE-CAUSING FACTOR AND USE THEREOF

Resumen de: US2025250324A1

A fusion protein of the present disclosure may induce the degradation of neurodegenerative disease-causing factors by binding to Tau and amyloid-beta proteins as the neurodegenerative disease-causing factors and activating autophagy. In addition, the fusion protein of the present disclosure penetrates a blood-brain barrier and is introduced into cells to be effectively delivered into nerve cells without a separate carrier, and has high stability and thus is expected to be used as a platform for the treatment of neurodegenerative diseases such as dementia and Alzheimer's disease.

Methods for Providing Rapid Relief of Motor Fluctuations in a Parkinson's Disease Patient

Resumen de: US2025248960A1

The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.

USE OF MESENCHYMAL-STEM-CELL-DERIVED INTRACELLULAR NANOVESICLE IN NEUROPROTECTION

Resumen de: WO2025162163A1

Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.

FTO INHIBITORS OF BICYCLIC STRUCTURES

Resumen de: WO2025162358A1

Disclosed herein is a compound of Formulas (I) and (II) as an FTO inhibitor with novel structures. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

COMPOUND FOR RECOGNIZING α-SYNUCLEIN AGGREGATE, AND USE THEREOF

Resumen de: WO2025162452A1

A compound specifically binding to an α-synuclein aggregate, and a preparation method therefor and the use thereof. Specifically, the compound binding to the α-synuclein aggregate comprises compounds as shown in formula A or sub-general formulas thereof, or stereoisomers, pharmaceutically acceptable salts, solvates or stable isotope variants thereof. The compound is a small molecule tracer, which can specifically recognize the α-synuclein aggregate, and can be used for the preparation of a drug for the treatment or diagnosis of neurodegenerative diseases (such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and progressive muscular atrophy) related to the α-synuclein aggregate and other misfolded proteins.

C-17 CARBONYL-SUBSTITUTED OLEANANE TRITERPENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025162103A1

The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating/preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.

C17-SITE NITROGEN-SUBSTITUTED AND METHYLENE-SUBSTITUTED OLEANANE TRITERPENE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2025162101A1

A C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2-Leap1 decoupling agent, and a use of the compound in the preparation of a medicament for preventing and/or treating diseases in a patient, the diseases comprising cerebral small vessel disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, cognitive impairment in schizophrenia, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc.

ARYL HETEROCYCLIC KV1.3 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Nº publicación: WO2025161144A1 07/08/2025

Solicitante:

SHANGHAI SHENSHI WISE TECH CO LTD [CN]
\u4E0A\u6D77\u6DF1\u52BF\u552F\u601D\u79D1\u6280\u6709\u9650\u8D23\u4EFB\u516C\u53F8

Resumen de: WO2025161144A1

The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.